IEX · Idex
314 filings
IEX 8-K Current Reports
Idex - 314 current reports
IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 28, 2016
- 8-K · Feb 3, 2016
- 8-K · Feb 10, 2016
- 10-K · Feb 19, 2016
- 8-K · Feb 19, 2016
- 8-K · Mar 18, 2016
- 8-K · Apr 12, 2016
- 8-K · Apr 19, 2016
- 10-Q · Apr 25, 2016
- 8-K · Apr 25, 2016
- 8-K · Jun 15, 2016
- 8-K · Jul 19, 2016
- 8-K · Jul 25, 2016
- 8-K · Jul 28, 2016
- 10-Q · Aug 1, 2016
- 8-K · Sep 2, 2016
- 8-K · Oct 18, 2016
- 8-K · Oct 21, 2016
- 10-Q · Oct 25, 2016
- 8-K · Nov 8, 2016
- 8-K · Jan 4, 2017
- 8-K · Jan 31, 2017
- 8-K · Feb 2, 2017
- 10-K · Feb 23, 2017
- 8-K · Feb 23, 2017
- 8-K/A · Mar 8, 2017
- 8-K · Apr 20, 2017
- 8-K · Apr 25, 2017
- 10-Q · Apr 26, 2017
- 8-K · Apr 27, 2017
- 8-K · Jul 26, 2017
- 10-Q · Jul 26, 2017
- 8-K · Jul 28, 2017
- 8-K · Oct 17, 2017
- 8-K · Oct 20, 2017
- 10-Q · Oct 23, 2017
- 8-K · Jan 2, 2018
- 8-K · Jan 30, 2018
- 8-K · Feb 2, 2018
- 10-K · Feb 22, 2018
- 8-K · Apr 30, 2018
- 8-K · Apr 30, 2018
- 10-Q · Apr 30, 2018
- 8-K · May 3, 2018
- 8-K · Jul 25, 2018
- 10-Q · Jul 25, 2018
- 8-K · Jul 30, 2018
- 8-K · Oct 24, 2018
- 10-Q · Oct 24, 2018
- 8-K · Jan 30, 2019
- 10-K · Feb 28, 2019
- 10-Q · Apr 26, 2019
- 8-K · Apr 26, 2019
- 8-K · May 14, 2019
- 8-K · Jun 4, 2019
- 8-K · Jun 18, 2019
- 10-Q · Jul 26, 2019
- 8-K · Jul 26, 2019
- 10-Q · Oct 30, 2019
- 8-K · Oct 30, 2019
- 8-K · Jan 30, 2020
- 10-K · Feb 21, 2020
- 8-K · Feb 26, 2020
- 8-K · Apr 24, 2020
- 10-Q · Apr 24, 2020
- 8-K · Apr 29, 2020
- 8-K · May 13, 2020
- 10-Q · Jul 24, 2020
- 8-K · Jul 24, 2020
- 8-K · Oct 28, 2020
- 8-K · Oct 28, 2020
- 10-Q · Oct 28, 2020
- 8-K · Jan 13, 2021
- 8-K · Feb 1, 2021
- 8-K · Feb 1, 2021
- 8-K · Feb 4, 2021
- 8-K/A · Feb 10, 2021
- 10-K · Feb 25, 2021
- 8-K · Feb 26, 2021
- 8-K · Apr 28, 2021
- 8-K · Apr 28, 2021
- 10-Q · Apr 28, 2021
- 8-K · May 10, 2021
- 8-K · May 14, 2021
- 8-K · May 18, 2021
- 8-K · May 28, 2021
- 8-K · Jun 17, 2021
- 8-K · Jun 21, 2021
- 8-K · Jul 2, 2021
- 8-K · Jul 28, 2021
- 10-Q · Jul 28, 2021
- 8-K · Aug 26, 2021
- 10-Q · Oct 27, 2021
- 8-K · Oct 27, 2021
- 8-K · Feb 2, 2022
- 8-K · Feb 8, 2022
- 10-K · Feb 24, 2022
- 8-K · Feb 28, 2022
- 10-Q · Apr 27, 2022
- 8-K · Apr 27, 2022
- 8-K · May 10, 2022
- 8-K · Jun 16, 2022
- 10-Q · Jul 27, 2022
- 8-K · Jul 27, 2022
- 8-K · Sep 13, 2022
- 8-K · Sep 22, 2022
- 8-K · Oct 26, 2022
- 10-Q · Oct 26, 2022
- 8-K · Nov 2, 2022
- 8-K · Nov 17, 2022
- 8-K · Nov 18, 2022
- 8-K · Dec 16, 2022
- 8-K · Feb 1, 2023
- 10-K · Feb 23, 2023
- 10-Q · Apr 27, 2023
- 8-K · Apr 27, 2023
- 8-K · May 31, 2023
- 8-K · Jun 14, 2023
- 10-Q · Jul 27, 2023
- 8-K · Jul 27, 2023
- 8-K · Aug 30, 2023
- 8-K · Aug 30, 2023
- 8-K · Oct 25, 2023
- 8-K · Oct 26, 2023
- 10-Q · Oct 26, 2023
- 8-K · Feb 7, 2024
- 10-K · Feb 22, 2024
- 10-Q · Apr 24, 2024
- 8-K · Apr 24, 2024
- 8-K · May 8, 2024
- 8-K · Jul 23, 2024
- 8-K · Aug 1, 2024
- 10-Q · Aug 1, 2024
- 8-K · Aug 8, 2024
- 8-K · Aug 21, 2024
- 8-K · Sep 5, 2024
- 10-Q · Oct 30, 2024
- 8-K · Oct 30, 2024
- 8-K · Feb 4, 2025
- 8-K · Feb 20, 2025
- 10-K · Feb 20, 2025
- 8-K · May 1, 2025
- 10-Q · May 1, 2025
- 8-K · May 12, 2025
- 8-K · May 21, 2025
- 10-Q · Jul 30, 2025
- 8-K · Jul 30, 2025
- 8-K · Sep 18, 2025
- 8-K · Oct 29, 2025
- 10-Q · Oct 29, 2025
- 8-K · Dec 4, 2025
- 8-K · Feb 4, 2026
- 8-K · Feb 9, 2026
- 10-K · Feb 19, 2026
- 8-K · Apr 29, 2026
- 10-Q · Apr 29, 2026
- 8-K · May 8, 2026
- 8-K · Jul 29, 2026
- 10-Q · Jul 29, 2026
- 8-K · Aug 17, 2026
- 8-K · Sep 3, 2026
- 8-K · Oct 28, 2026
- 10-Q · Oct 28, 2026
Idex 8-K Report, Financial Results (Oct 28, 2026)
IDEX Corporation reported record third-quarter 2026 results, with net sales of $951.7 million, up 8% on both a reported and organic basis versus the prior year period. Reported diluted EPS attributable to IDEX was $1.95, up from $1.70, and record adjusted diluted EPS was $2.33, up from $2.03, with both reported and adjusted EPS increasing 15%. Orders were $991.2 million, up 13% on both a reported and organic basis. Gross margin rose to 45.1% from 44.5%, and Adjusted EBITDA margin rose to 27.8% from 27.3%. The Health & Science Technologies segment drove much of the growth, with net sales up 14% and organic sales up 13%, supported by AI-driven demand for data center power and semiconductor markets, as well as space and defense. Cash flow was strong, with operating cash flow of $239.5 million and free cash flow of $214.3 million, compared with $188.7 million a year earlier. The company returned $129 million to shareholders through dividends and share repurchases during the quarter, and it amended and restated its $800 million revolving credit facility to extend maturity to September 2031. Management raised full-year 2026 guidance, now projecting organic sales growth of 6.5% to 6.8%, up from 5% to 6%, and adjusted diluted EPS of $8.91 to $8.96, up from $8.70 to $8.85. The filing furnishes the earnings press release as Exhibit 99.1 under Item 2.02, and that information is not deemed filed for Section 18 purposes.
Idex 8-K Report, Material Agreement (Sep 3, 2026)
On September 3, 2026, IDEX Corporation entered into an amended and restated credit agreement, dated as of November 1, 2022, with Bank of America, N.A. as administrative agent, swingline lender and letter of credit issuer, together with its subsidiaries as borrowers and a group of lenders and financial institutions. The filing describes the agreement as consisting of an $800 million revolving credit facility with a final maturity date of September 3, 2031. That date extends the November 1, 2027 maturity of the original agreement, and the maturity may be further extended twice, each time by one year, under certain conditions. The facility can be used for working capital and general corporate purposes, including refinancing existing company and subsidiary debt. It includes a sublimit of up to $100 million for letters of credit and up to $50 million for same-day swingline loans. The company may request commitment increases of up to $400 million in aggregate, and may designate certain foreign subsidiaries as borrowers, in which case it must guarantee their obligations. Borrowings bear interest at an alternate base rate or Term SOFR (or applicable alternative currency rates) plus an applicable margin, which is based on the better of the company's senior unsecured long-term debt rating or its leverage ratio. Voluntary prepayments and commitment reductions are permitted without penalty, subject to break funding payments and minimum notice and amount requirements. The agreement contains customary senior unsecured covenants, including a leverage ratio tested quarterly, with an option to increase the ratio for 12 months following certain acquisitions. Negative covenants restrict liens, fundamental changes such as mergers or sales of substantially all assets, certain subsidiary dividends, materially different lines of business, and certain subsidiary debt. The agreement also includes customary events of default, subject to grace periods. The filing notes that the company and the lenders maintain other commercial and investment banking relationships. The full agreement is filed as Exhibit 10.1, with certain schedules omitted under Item 601(a)(5) of Regulation S-K.
Idex 8-K Report, Executive Changes (Aug 17, 2026)
IDEX Corporation filed a Current Report on Form 8-K dated August 17, 2026, under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). The filing reports that L. Paris Watts-Stanfield resigned from the Board of Directors effective immediately on August 13, 2026. The filing states that Ms. Watts-Stanfield's decision to resign was not the result of any disagreement with the Company on any matters relating to its operations, policies or practices. The Company and the Board thanked her for her service. In connection with the resignation, the size of the Board was reduced from ten to nine directors. This is a governance-related disclosure. The filing does not announce a replacement director, a new officer appointment, or any compensatory arrangement changes.
Idex 8-K Report, Financial Results (Jul 29, 2026)
IDEX Corporation reported second-quarter 2026 results on July 29, 2026, with record sales of $921 million, up 6% on a reported basis and 5% organically. Net sales were $920.6 million versus $865.4 million a year earlier. Reported diluted EPS was $1.93, up from $1.74, and adjusted diluted EPS was a record $2.32, up 12% from $2.07. Record orders exceeded $1 billion ("$1,071.6 million"), up 29% on a reported basis and 28% organically. Health & Science Technologies drove growth, with net sales up 14% and organic sales up 12%, driven by AI-related data center power and semiconductor demand, space and defense, and positive price. The quarter included a net benefit from IEEPA tariff refunds. The filing says these refunds contributed 150 basis points to gross margin and added $0.08 to both reported and adjusted diluted EPS, partly offset by a $14.7 million reduction in net sales from expected customer rebates tied to the refunds. Operating cash flow was $200.0 million and free cash flow was $177.0 million, up from $146.9 million. The company returned $77 million through share repurchases and paid $54 million in dividends during the quarter. Management raised its full-year 2026 guidance, now projecting organic sales growth of 5% to 6% (previously 3% to 4%) and adjusted diluted EPS of $8.70 to $8.85 (previously $8.35 to $8.55). Third-quarter guidance calls for organic sales growth of 5% to 7% and adjusted diluted EPS of $2.20 to $2.25. The filing attributes the raised outlook to strong year-to-date performance and improved second-half visibility.
Idex 8-K Report, Shareholder Vote Results (May 8, 2026)
IDEX Corporation held its Annual Meeting of Stockholders on May 6, 2026, and reported the results of three shareholder votes in this Form 8-K. Stockholders elected four Class I directors, Mark A. Beck, Carl R. Christenson, Katrina L. Helmkamp and Alejandro Quiroz Centeno, to three-year terms expiring at the 2029 annual meeting. Beck received 62,032,187 votes for and 4,324,559 against, while Quiroz Centeno received 65,577,289 for and 778,817 against. Stockholders also approved, on an advisory basis, the compensation of the company's named executive officers, with 58,071,019 affirmative votes, 7,464,627 negative votes, 829,154 abstentions and 1,305,842 broker non-votes. The proposal to ratify Deloitte & Touche LLP as the independent registered public accounting firm for 2026 received 58,038,340 affirmative votes, 9,627,072 negative votes and 5,230 abstentions. Each proposal received the affirmative vote of a majority of the shares present in person or represented by proxy and entitled to vote on the matter. The filing reports governance outcomes only. It contains no financial results, guidance or other operating information, and its single exhibit is the Inline XBRL cover page.
Idex 8-K Report, Financial Results (Apr 29, 2026)
IDEX Corporation reported first quarter 2026 results for the three months ended March 31, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K. Net sales were $886.9 million, up 9% on a reported basis and 5% organically, versus $814.3 million in the prior year period. Orders were a record $988.3 million, up 13% reported and 10% organically. GAAP diluted EPS was $1.61 (up from $1.26), and adjusted diluted EPS was $2.00 (up from $1.75, or 14%). Gross margin declined to 44.9% from 45.3%, citing unfavorable mix and pressured price/cost, partly offset by productivity and volume leverage. Health & Science Technologies drove growth, with segment organic sales up 11%, attributed to AI-driven demand for data center power and semiconductor markets as well as strength in space and defense, partially offset by lower life sciences volumes. Cash generation was softer. Operating cash flow was $103.7 million versus $105.7 million, and free cash flow was $86.0 million versus $91.4 million, reflecting the timing of customer payments and higher capital expenditures. The company returned $76 million through share repurchases and $53 million through dividends during the quarter. Total borrowings rose, with $100.0 million drawn under revolving credit facilities during the period, and long-term borrowings-net increased to $1,871.8 million from $1,820.1 million at year-end 2025. Management raised its full-year 2026 guidance, now projecting organic sales growth of 3% to 4% (up from 1% to 2%) and adjusted diluted EPS of $8.35 to $8.55 (up from $8.15 to $8.35). Second quarter 2026 guidance calls for organic sales growth of 3% to 4% and adjusted diluted EPS of $2.07 to $2.12.
Idex 8-K Report, Executive Changes (Feb 9, 2026)
IDEX Corporation filed a Form 8-K under Item 5.02, which covers departures of directors or principal officers and compensatory arrangements for certain officers. The filing discloses a leadership change: on February 4, 2026, the company notified Roopa Unnikrishnan, Senior Vice President, Chief Strategy and Innovation Officer and a current named executive officer, that her position was being eliminated, effective February 28, 2026. The filing states that the company expects to enter into a separation agreement with Ms. Unnikrishnan under the terms of her letter agreement with the company for a termination without cause. The filing refers investors to the company's Proxy Statement filed with the SEC on March 26, 2025, for a description of that letter agreement. The 8-K does not disclose separation payment amounts or other financial terms. For investors, the key takeaway is a senior strategy executive's role being eliminated, with her departure effective at the end of February 2026. The filing does not state the reasons for the position's elimination or name a successor.
Idex 8-K Report, Financial Results (Feb 4, 2026)
IDEX Corporation (NYSE: IEX) furnished an 8-K on February 4, 2026, attaching a press release reporting fourth-quarter and full-year 2025 results. For the full year, net sales were $3,457.5 million, up 6% on a reported basis and 1% organically, with reported diluted EPS of $6.41 (down from $6.64) and adjusted diluted EPS of $7.95 (up from $7.89). Net income attributable to IDEX was $483.2 million versus $505.0 million in 2024, reflecting higher depreciation, amortization, restructuring costs, interest expense and taxes. The company cited a higher effective tax rate tied to 2025 legislation. Fourth-quarter net sales were $899.1 million, up 4% reported and 1% organic, and orders reached a record $979.2 million, up 20% reported and 16% organically, driven mostly by the HST segment. Management attributed HST order growth to AI-related projects, including data center power and semiconductor applications, while describing FMT and FSDP as operating in a challenging demand environment. Cash flow from operations for the year was $680.4 million and free cash flow was $616.8 million, with $247.8 million used for share repurchases. Free cash flow conversion was 103%. For 2026, IDEX projects full-year organic sales growth of 1% to 2% and adjusted diluted EPS of $8.15 to $8.35, and first-quarter organic sales growth of approximately 1% with adjusted diluted EPS of $1.73 to $1.78. The company does not reconcile these forward-looking non-GAAP measures to GAAP because the timing and magnitude of certain items cannot be reasonably estimated.
Idex 8-K Report, Executive Changes (Dec 4, 2025)
IDEX Corporation announced on December 4, 2025 that Sean M. Gillen, currently Chief Financial Officer of AAR CORP., will join as Senior Vice President and Chief Financial Officer effective January 5, 2026. Akhil Mahendra, who has served as Interim Chief Financial Officer, will return to his role as Vice President, Corporate Development on that date. The filing discloses Mr. Gillen's offer letter dated December 1, 2025, which provides an initial base salary of $625,000, a management incentive target of 85% of base salary beginning with the 2026 program, an annual equity grant with a targeted grant date fair value of $2,000,000, a new hire restricted stock award with a grant date fair value of $3,000,000 vesting in one-third installments on each anniversary of the grant date, and a cash sign-on bonus of $325,000 subject to repayment if he leaves or is terminated for cause before the 12-month anniversary of his start date. The filing also reports that Melissa S. Flores, Senior Vice President and Chief Human Resources Officer and a named executive officer, will resign effective December 19, 2025 to pursue another employment opportunity. According to the accompanying press release, the company intends to fill the role externally with a focus on talent strategy and culture, while leveraging existing leadership to oversee HR operations and administration in the interim. The press release (Exhibit 99.1) furnished under Item 7.01 quotes CEO Eric Ashleman describing the appointment as supporting the company's enterprise strategy, growth sectors, and 8020 approach. Mr. Gillen's stated priorities include improving margins and building on growth markets.
Idex 8-K Report, Financial Results (Oct 29, 2025)
IDEX Corporation reported third-quarter 2025 results for the period ended September 30, 2025, in a press release furnished as Exhibit 99.1 under Item 2.02. Record net sales were $878.7 million, up 10% on a reported basis and 5% organically, with the increase largely driven by the Mott Corporation acquisition completed in September 2024. Reported diluted EPS was $1.70 (up from $1.57), and adjusted diluted EPS was $2.03 (up from $1.90). Record orders were $880.3 million, up 13% reported and 7% organically. Gross margin was relatively flat at 44.5%, and operating cash flow of $203.5 million and free cash flow of $188.7 million were both roughly flat versus the prior year period. The company narrowed its full-year 2025 outlook, with GAAP diluted EPS now expected at $6.35 to $6.40 and adjusted diluted EPS at $7.86 to $7.91, both within prior guidance ranges. Full-year organic sales growth of approximately 1% was unchanged, and management expects at least 100% free cash flow conversion for the year and $60+ million in full-year savings from platform optimization and cost containment actions. Results were mixed by segment: Health & Science Technologies net sales rose 22% reported and 10% organically, Fluid & Metering Technologies rose 5% reported and 4% organically, and Fire & Safety/Diversified Products declined 3% reported and 5% organically. Capital deployment remained active. The company repurchased 461,500 shares for $75.0 million in the third quarter and $175 million year-to-date, increased its share repurchase authorization to $1 billion, and completed the Micro-LAM, Inc. acquisition for cash consideration of $80.7 million in July 2025. Interest expense rose to $16.5 million in the quarter from $10.3 million, reflecting debt raised for the Mott acquisition.
Idex 8-K Report, Regulation FD Disclosure (Sep 18, 2025)
On September 17, 2025, IDEX Corporation's Board of Directors authorized an additional $635 million share repurchase. Combined with the approximately $365 million that remained under previously approved authorizations, the company now has total repurchase availability of approximately $1 billion. The press release notes that this compares with approximately $440 million remaining as of June 30, 2025. The repurchases may be made in open market transactions, in privately negotiated transactions, or under 10b5-1 plans. Timing, volume and nature will be at management's discretion and depend on market conditions, other cash investment priorities, securities laws and other factors. The program does not obligate IDEX to buy any particular amount of stock and may be suspended or discontinued at any time. In the same release, IDEX's Board approved a regular quarterly cash dividend of $0.71 per common share, payable October 24, 2025 to shareholders of record as of October 10, 2025. This is the company's 124th consecutive regular quarterly cash dividend. CEO Eric D. Ashleman said IDEX expects to return at least 70% of free cash flow to shareholders in 2025 through dividends and repurchases, and that the company intends to deploy free cash flow toward bolt-on acquisitions and shareholder returns. He also noted that IDEX repurchased over $100 million of stock in the first half of 2025.
Idex 8-K Report, Financial Results (Jul 30, 2025)
IDEX Corporation reported second-quarter 2025 results for the period ended June 30, 2025, with record net sales of $865.4 million, up 7% on a reported basis and 1% organically. Reported diluted EPS was $1.74, down from $1.86 a year earlier, while adjusted diluted EPS was $2.07, essentially flat versus $2.06. Orders were $829.8 million, up 7% reported and 2% organically, which management described as below the year-to-date average. Net sales growth was driven mainly by the Mott Corporation acquisition, while organic growth reflected positive price and targeted growth initiatives, partly offset by lower volumes in the Fluid & Metering Technologies segment. Management lowered its full-year 2025 outlook to GAAP diluted EPS of $6.30 to $6.44 and adjusted diluted EPS of $7.85 to $7.95, down from prior guidance of $6.56 to $6.95 and $8.10 to $8.45 respectively, based on expected full-year organic sales growth of approximately 1%. The CEO attributed the reset to a downshift in rapid-turn order trends exiting the quarter and customers taking a more cautious stance on larger orders, which delayed expected second-half acceleration in recently acquired businesses. For the third quarter, the company guided to GAAP diluted EPS of $1.54 to $1.61 and adjusted diluted EPS of $1.90 to $1.95, with organic sales growth of 2% to 3%. Cash generation improved, with operating cash flow of $161.7 million in the quarter, up from $133.6 million, and free cash flow of $146.9 million, up from $117.7 million. During the period the company repurchased 268,586 shares for $50.0 million in May 2025 and repaid $100.0 million of 3.37% Senior Notes in June 2025. In July 2025 it acquired Micro-LAM, Inc. for $90.0 million in cash plus a potential earnout of up to $12.0 million.
Idex 8-K Report, Executive Changes (May 21, 2025)
IDEX Corporation filed this Form 8-K under Item 5.02 to report a leadership change in its finance function. On May 19, 2025, Abhishek Khandelwal, Senior Vice President and Chief Financial Officer, notified the Company of his decision to resign, effective May 30, 2025, to pursue a new professional opportunity. The filing states that his departure is not the result of any disagreement with the Company's independent auditors or management on accounting principles, financial statement disclosure, or internal controls. The Company has retained an external search firm to identify candidates for the CFO role. On May 20, 2025, the Company appointed Akhil Mahendra as interim Chief Financial Officer, effective May 30, 2025, serving until a successor is appointed. Mahendra, 44, has been with the Company for approximately two years as Vice President, Corporate Development, and will continue in that role during the interim period. Previously he was Vice President, Corporate Development at Rivian Automotive, Inc. from 2020 to 2023, and before that worked in investment banking at Morgan Stanley. He holds a B.S. in Mechanical Engineering from Kettering University and an MBA from the University of Michigan. In connection with his interim appointment, the Compensation Committee approved a restricted stock award to Mahendra with a grant date fair value of $500,000. The award cliff vests three years after the grant date, subject to continued service, except as otherwise provided in the award agreement. The filing states there are no arrangements or understandings tied to his appointment, no family relationships with directors or executive officers, and no related-person transactions requiring disclosure under Item 404(a) of Regulation S-K.
Idex 8-K Report, Shareholder Vote Results (May 12, 2025)
IDEX Corporation's 8-K reports the results of its Annual Meeting of Stockholders, held May 8, 2025. Stockholders elected three Class III directors, Eric D. Ashleman, Stephanie J. Disher and Matthijs Glastra, to three-year terms expiring at the 2028 annual meeting. Each director received more votes for than against, but Disher drew the most opposition, with 3,347,060 votes against. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 59,216,982 votes in favor and 7,714,378 against. They ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2025, with 60,637,663 votes in favor and 8,839,575 against. A stockholder proposal calling for a report on hiring practices related to people with arrest or incarceration records did not pass, receiving 9,437,823 votes in favor and 55,577,864 against. The filing contains no financial results or operating disclosures. Its only listed exhibit is the Cover Page Interactive Data File (Exhibit 104).
Idex 8-K Report, Financial Results (May 1, 2025)
IDEX Corporation reported first-quarter 2025 results for the three months ended March 31, 2025, in a press release furnished as Exhibit 99.1 under Item 2.02. Orders were $871.9 million, up 6% from $820.3 million, with organic orders up 1%. Net sales were $814.3 million, up 2% from $800.5 million, but organic sales decreased 1%, driven by lower volumes in certain Fluid & Metering Technologies and Health & Science Technologies businesses. Reported diluted EPS was $1.26 versus $1.60 a year earlier, and adjusted diluted EPS was $1.75 versus $1.88. Net income attributable to IDEX was $95.5 million, down from $121.4 million, reflecting higher interest expense, depreciation, a higher effective tax rate, and higher restructuring and amortization costs. Management maintained its full-year 2025 organic sales growth guidance of 1% to 3% and GAAP diluted EPS guidance of $6.56 to $6.95 (adjusted diluted EPS of $8.10 to $8.45). For the second quarter, it guided to GAAP diluted EPS of $1.60 to $1.72 and adjusted diluted EPS of $1.95 to $2.05, based on organic sales growth of 0% to 2%. Management said it identified an additional $20 million of cost containment actions to offset potential tariff-related volume pressure and later-stage demand pressure, and that platform optimization efforts are on track for a total of $43 million impact in 2025. Cash flow weakened, with operating cash flow of $105.7 million (down from $156.6 million) and free cash flow of $91.4 million (down from $136.6 million), reflecting higher inventory build and interest payments on senior notes issued to fund the Mott acquisition. The company repurchased 256,159 shares for $50.0 million in February 2025 and had $249.0 million outstanding under its revolving credit facility at March 31, 2025, after repayments in January and April 2025.
Idex 8-K Report, Executive Changes (Feb 20, 2025)
IDEX Corporation (NYSE: IEX) filed a Form 8-K on February 20, 2025 reporting board changes under Item 5.02. On February 19, 2025, the Board appointed Stephanie Disher and Matthijs Glastra as directors, effective February 21, 2025. Ms. Disher will serve on the Nominating and Corporate Governance Committee and Mr. Glastra on the Audit Committee. Ms. Disher is Chief Executive Officer of Atmus Filtration Technologies Inc., and Mr. Glastra is Chair and Chief Executive Officer of Novanta Inc. In the same notice, directors David C. Parry and Livingston L. Satterthwaite informed the Company they will retire from the Board immediately following the 2025 Annual Meeting of Stockholders and will not stand for re-election. The Board size will increase from 10 to 12 directors and then fall to 10 after the annual meeting concludes. The filing states that neither new director has familial relationships or related-party transactions requiring disclosure, and both will receive the standard non-employee director compensation described in the March 26, 2024 proxy statement. The filing attaches a press release dated February 20, 2025 announcing the appointments and retirements. The release describes IDEX as a company with about 9,000 employees, manufacturing operations in more than 20 countries, and approximately $3.3 billion in annual sales. The changes are governance-related and do not include any financial results or guidance in this filing.
Idex 8-K Report, Financial Results (Feb 4, 2025)
IDEX Corporation (NYSE: IEX) reported fourth quarter and full year 2024 results on February 4, 2025, furnished as Exhibit 99.1 to this Item 2.02 Form 8-K. For the quarter ended December 31, 2024, net sales rose to $862.9 million from $788.9 million, with orders of $816.8 million and organic sales up 3%. Reported diluted EPS was $1.62 versus $1.43, and adjusted diluted EPS was $2.04 versus $1.83. Operating cash flow fell to $172.6 million from $201.0 million, and free cash flow declined to $157.1 million from $179.4 million. Management attributed the sales increase largely to acquisitions, including Mott Corporation, and strong price capture. For full year 2024, net sales were $3,268.8 million, roughly flat with $3,273.9 million in 2023, and organic sales declined 2%. Net income attributable to IDEX fell to $505.0 million from $596.1 million, and reported diluted EPS was $6.64 versus $7.85. Adjusted diluted EPS was $7.89 versus $8.22. Operating cash flow was $668.1 million and free cash flow was $603.0 million, with free cash flow conversion of 101%. Health & Science Technologies saw softness in organic sales, while Fire & Safety/Diversified Products grew organically. For 2025, IDEX projected full-year organic sales growth of 1% to 3%, GAAP diluted EPS of $6.56 to $6.96, and adjusted diluted EPS of $8.10 to $8.45. First-quarter 2025 organic sales are projected to decline 3% to 4%, with GAAP diluted EPS of $1.18 to $1.24. Management cited geopolitical and economic uncertainty and reiterated a path toward double-digit earnings expansion.
Idex 8-K Report, Financial Results (Oct 30, 2024)
IDEX Corporation (NYSE: IEX) reported third-quarter 2024 results in a press release dated October 29, 2024, furnished with this Form 8-K. Net sales were $798.2 million, up 1% overall and flat on an organic basis, with lower volumes in the Health & Science Technologies segment offset by price capture. Orders rose to $780.5 million from $712.3 million, and organic orders increased 8%. Reported diluted EPS fell to $1.57 from $2.75, down 43%, mainly because the prior-year period included the gain on the sale of the Micropump business. Adjusted diluted EPS was $1.90, down 10%, and adjusted EBITDA margin was 26.9%, down 150 bps, as higher employee-related costs and lower volume outweighed price/cost gains. Operating cash flow was $205.3 million, down 9%, and free cash flow was $191.6 million, down 7%. The company completed its acquisition of Mott Corporation on September 5, 2024, for cash consideration of $986.2 million, net of $3.1 million of cash acquired. IDEX states that the net transaction value, after the present value of expected tax benefits of approximately $100 million, is about $900 million, or roughly 19x Mott's forecasted full-year 2024 EBITDA. The company expects the acquisition to be accretive to adjusted earnings per share in fiscal 2026. During the quarter, IDEX also completed a public offering of $500 million principal amount of 4.950% Senior Notes due September 2029. For full-year 2024, IDEX projects organic sales to decline 1% to 2%. It raised the low end of its adjusted diluted EPS guidance to $7.85 to $7.90 from $7.80 to $7.90, and lowered its GAAP diluted EPS guidance to $6.65 to $6.70 from $6.85 to $6.95. The company attributes the GAAP change to purchase accounting impacts, including acquisition-related amortization from Mott. Management stated that segment-level orders and backlog trends, particularly in Health & Science Technologies, will be key indicators to watch as the company looks for signs of recovery in life science and semiconductor markets.
Idex 8-K Report, Regulation FD Disclosure (Sep 5, 2024)
IDEX Corporation, a Delaware corporation headquartered in Northbrook, Illinois, reported in this Form 8-K dated September 5, 2024 that it completed its previously announced acquisition of Mott Corporation, a Connecticut corporation, and its subsidiaries. The filing furnishes a press release (Exhibit 99.1) under Item 7.01 and reports the closing under Item 8.01 (Other Events). The filing does not state the purchase price or other deal financial terms. According to the press release, Mott is a leader in the design and manufacturing of sintered porous material structures and flow control solutions, with more than 60 years of history serving global OEMs and technology brands. IDEX expects Mott to join its Health & Science Technologies segment, expanding its applied material science capabilities and increasing opportunities in semiconductor wafer fabrication equipment, energy transition, medical technologies, space & defense, and water purification. Management also expects the acquisition to complement recent integrations of Muon Group, Iridian Spectral Technologies, and STC Material Solutions, and to create value through implementation of 8020 and the IDEX Operating Model. CEO Eric D. Ashleman described the deal as an important step in IDEX's strategy to deliver long-term, compounding value to customers, employees, and shareholders. The press release notes that IDEX has approximately $3.3 billion in annual sales and about 8,800 employees across more than 50 businesses. The filing does not disclose Mott's revenue, earnings, or the financial effect of the transaction on IDEX's results.
Idex 8-K Report, Material Agreement (Aug 21, 2024)
IDEX Corporation completed an underwritten public offering on August 21, 2024 of $500.0 million aggregate principal amount of 4.950% Senior Notes due 2029, issued under a shelf registration statement on Form S-3ASR. Net proceeds were approximately $495.0 million after the underwriting discount and estimated offering expenses of approximately $1.7 million. The company intends to use the proceeds, together with revolving credit facility borrowings and cash on hand, to fund the cash consideration for its previously announced acquisition of Mott Corporation and its subsidiaries (the "Mott Acquisition") and to pay related fees and expenses. The Notes are senior, unsecured obligations, equal in right of payment with the company's existing and future senior unsecured debt and senior to subordinated debt. They are effectively subordinated to future secured debt and structurally subordinated to all liabilities of subsidiaries, since the Notes are not guaranteed by any subsidiary. Interest is payable semi-annually on March 1 and September 1, beginning March 1, 2025, with maturity on September 1, 2029. The company may redeem the Notes before the August 1, 2029 par call date at a make-whole price based on the Treasury Rate plus 20 basis points, and at 100% of principal thereafter. The Indenture includes covenants limiting liens, certain sale-leaseback transactions, and certain consolidations, mergers, or asset sales. A special mandatory redemption provision requires the company to redeem all Notes at 101% of principal plus accrued interest if the Mott Acquisition is not consummated by the Special Mandatory Redemption End Date (the later of November 20, 2024, or any extended outside date under the Mott Acquisition Agreement), if that agreement is terminated without closing, or if the company notifies the trustee it will not pursue the acquisition. A change of control triggering event requires an offer to repurchase at 101% of principal plus accrued interest.
Idex 8-K Report, Material Agreement (Aug 8, 2024)
IDEX Corporation entered into an Underwriting Agreement dated August 7, 2024 with Wells Fargo Securities, LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the several underwriters, under which the company agreed to issue and sell $500.0 million in aggregate principal amount of its 4.950% Senior Notes due 2029. The underwriters agreed to purchase the notes for resale to the public. The offering is expected to close on August 21, 2024, subject to customary closing conditions. The notes are being offered under the company's effective shelf registration statement on Form S-3ASR (File No. 333-277309), filed February 23, 2024, and a related prospectus supplement filed August 7, 2024. They will be issued under a 2010 indenture with Computershare Trust Company, N.A., as successor trustee, as supplemented by a Fifth Supplemental Indenture to be dated the closing date. IDEX intends to use the net proceeds, together with available revolving credit facility borrowings and cash on hand, to fund the cash consideration for its previously announced acquisition of Mott Corporation and its subsidiaries, and to pay related fees and expenses. The underwriting agreement contains customary representations, warranties, covenants, and indemnification provisions. Certain underwriters and their affiliates have provided, and may in the future provide, commercial banking, derivatives, advisory, and other services to the company for customary fees.
Idex 8-K Report, Financial Results (Aug 1, 2024)
IDEX Corporation reported second-quarter 2024 net sales of $807 million, down 5% overall and down 4% organically, against $846 million a year earlier. Reported diluted EPS rose to $1.86 from $1.82, while adjusted diluted EPS fell 6% to $2.06. Gross margin increased 70 bps to 45.4%, driven mainly by price/cost and operational productivity, while adjusted EBITDA margin declined 60 bps to 27.8%, reflecting lower volume leverage and unfavorable mix. Operating cash flow was $134 million, down 5%, and free cash flow was $118 million, down 2%. The Health & Science Technologies segment, with organic net sales down 11%, was the main source of weakness, while Fluid & Metering Technologies was flat organically and Fire & Safety/Diversified Products rose 1%. The company lowered its full-year 2024 outlook. Organic sales are now projected to decline 1% to 2%, versus prior guidance of an increase of 0% to 2%. GAAP diluted EPS guidance is $6.85 to $6.95 (adjusted $7.80 to $7.90), down from $7.13 to $7.43 (adjusted $8.15 to $8.45). For the third quarter, organic sales are projected to be 0% to 1% higher year over year, with GAAP diluted EPS of $1.61 to $1.66 and adjusted diluted EPS of $1.85 to $1.90. Management cited uncertainty-fueled macro headwinds and project delays in industrial markets, and noted that the Semiconductor and Life Sciences & Analytical Instrumentation markets have not yet launched a recovery. On capital deployment, IDEX entered into a definitive agreement on July 23, 2024 to acquire Mott Corporation and its subsidiaries for $1.0 billion in cash, subject to customary adjustments, with closing expected by the end of the third quarter of 2024. The company also divested Alfa Valvole Srl for $45.5 million in cash, recognizing a gain of $4.6 million, and repaid $25.0 million of the $50.0 million outstanding under its term facility. Cash and cash equivalents were $700.7 million at June 30, 2024, compared with $534.3 million at December 31, 2023.
Idex 8-K Report, Regulation FD Disclosure (Jul 23, 2024)
IDEX Corporation (NYSE: IEX) has entered into a definitive agreement to acquire Mott Corporation and its subsidiaries from the Mott Corporation Employee Stock Ownership Trust, for cash consideration of $1 billion, subject to customary adjustments. Mott is described as a leading microfiltration business specializing in the design, customization, and manufacturing of sintered porous metal components and engineered solutions used in fluidic applications. Adjusted for the present value of expected tax benefits of approximately $100 million, the net transaction value is approximately $900 million, which the company says represents approximately 19x Mott's forecasted full year 2024 EBITDA and a mid-teens multiple based on forecasted 2025 EBITDA. IDEX expects Mott to generate approximately $200 million of revenue in 2024 with an EBITDA margin in the low 20s, and will fold it into its Health & Science Technologies segment. The transaction is expected to be accretive to adjusted earnings per share in fiscal 2026 and to deliver a double-digit return on invested capital in year five after closing. Management frames the deal as an extension of its applied materials science portfolio, alongside the recently acquired Muon Group, Iridian Spectral Technologies, and STC Material Solutions, with target markets including semiconductor wafer fab equipment, energy transition, medical technologies, space and defense, and water purification. The transaction will be funded through cash on hand, borrowings under IDEX's current credit facility, and potential debt issuance, and is not subject to any financing conditions. The company expects net leverage of approximately 1.8x at closing. Closing is expected by the end of the third quarter of 2024, subject to regulatory approvals and customary closing conditions.
Idex 8-K Report, Shareholder Vote Results (May 8, 2024)
IDEX Corporation reported the results of its Annual Meeting of Stockholders, held May 7, 2024, in an Item 5.07 disclosure. Stockholders elected three Class II directors, Mark A. Buthman, Lakecia N. Gunter and L. Paris Watts-Stanfield, to three-year terms expiring at the 2027 annual meeting. Each received more votes for than against, with Watts-Stanfield receiving the widest margin, at 68,179,259 for and 403,994 against. Stockholders also voted on three company proposals. They approved, on an advisory basis, the compensation of the named executive officers (61,787,864 affirmative votes versus 5,922,861 negative), approved the IDEX Corporation 2024 Incentive Award Plan (62,284,526 affirmative versus 5,427,757 negative), and ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2024 (63,061,818 affirmative versus 7,014,160 negative). A stockholder proposal calling for a report on hiring practices related to people with arrest or incarceration records did not pass. It received 11,130,090 affirmative votes against 54,948,151 negative votes, with 2,514,544 abstentions and 1,531,949 broker non-votes. The filing also lists a Cover Page Interactive Data File (Exhibit 104) as its only exhibit.
Idex 8-K Report, Financial Results (Apr 24, 2024)
IDEX Corporation reported first-quarter 2024 results for the period ended March 31, 2024, with net sales of $800.5 million, down 5% overall and down 6% on an organic basis, which the filing describes as in line with expectations. Reported diluted EPS was $1.60 versus $1.84 a year earlier, and adjusted diluted EPS was $1.88 versus $2.09, which the company says exceeded first-quarter expectations. Operating cash flow was $156.6 million and free cash flow was $136.6 million, up 15.3 million from the prior-year period, and the company reduced its net debt position through strong cash generation, with cash and cash equivalents rising to $616.3 million at quarter-end. By segment, Fluid & Metering Technologies (FMT) sales were $313.7 million and adjusted EBITDA margin improved to 33.6%, Fire & Safety/Diversified Products (FSDP) sales rose 2% organically to $178.0 million with margin expanding to 28.9%, and Health & Science Technologies (HST) sales fell 13% organically to $310.1 million with adjusted EBITDA margin declining 250 bps to 26.2%. Management cited an encouraging sequential lift in orders from core industrial and municipal markets, while noting uneven recovery across HST's targeted end markets. IDEX confirmed its full-year 2024 guidance, projecting organic sales growth of 0% to 2%, GAAP diluted EPS of $7.13 to $7.43, and adjusted diluted EPS of $8.15 to $8.45. For the second quarter, it projects organic sales declines of 2% to 3% and adjusted diluted EPS of $2.00 to $2.05.
Idex 8-K Report, Financial Results (Feb 7, 2024)
IDEX Corporation (NYSE: IEX) reported fourth quarter and full year 2023 results in a press release dated February 6, 2024 (Exhibit 99.1), with slides for its February 7, 2024 earnings call furnished as Exhibit 99.2. For Q4 2023, sales were $788.9 million, down 3% overall and down 6% organically, while reported diluted EPS was $1.43 (down 16%) and adjusted diluted EPS was $1.83 (down 9%). Operating cash flow of $201.0 million and free cash flow of $179.4 million were both up year over year. For full year 2023, the company reported record net sales of $3,273.9 million (up 3%, but down 1% organically), record reported diluted EPS of $7.85, record adjusted diluted EPS of $8.22 (up 1%), and record free cash flow of $626.8 million (up 28%). management said most end markets are stable and that the company is in the early stages of focused organic growth. However, the timing of recovery in its Life Sciences and Analytical Instrumentation businesses remains uncertain, which moderates the full-year growth outlook. Orders fell 6% in Q4 and 7% for the full year, with organic orders down 10% and 11% respectively. During the quarter the company completed the $202.0 million cash acquisition of STC Material Solutions and the sale of Novotema for $8.3 million, which produced a $9.1 million loss. For 2024, IDEX guided to full-year organic sales growth of 0% to 2%, reported diluted EPS of $7.15 to $7.45, and adjusted diluted EPS of $8.15 to $8.45. First-quarter 2024 organic sales are projected to decline 6% to 7%, with adjusted diluted EPS of $1.70 to $1.75. Guidance excludes future acquisitions and restructuring expenses.
Idex 8-K Report, Financial Results (Oct 26, 2023)
IDEX Corporation (NYSE: IEX) reported third-quarter 2023 net sales of $793.4 million, down 4% overall and down 6% organically, compared with the third quarter of 2022. Reported diluted EPS was $2.75, up 17%, but adjusted diluted EPS was $2.12, down 1%, which management attributed in part to a lower effective tax rate. Operating cash flow was $227 million, up 14%, and free cash flow was a record $207 million, up 14%. Gross margin was 44.1%, down 220 basis points, driven mainly by the 2022 acceleration of deferred revenue tied to a COVID-19 testing application that did not recur in 2023, along with lower volume leverage and unfavorable mix. The company completed the sale of Micropump, Inc. for $110 million in cash, which produced a pre-tax gain of $93.8 million. During the quarter IDEX also repaid $150.0 million of the $200.0 million outstanding under its term facility. Management said the divergent destocking rates in its end markets have largely run their course, and it expects order rate stability for the balance of 2023. The company welcomed Abhi Khandelwal as SVP and Chief Financial Officer. IDEX raised its full-year 2023 guidance. Reported GAAP diluted EPS is now projected at $7.91 to $7.96, up from $6.80 to $6.90, and adjusted diluted EPS at $8.13 to $8.18, up from $7.90 to $8.00. Full-year organic sales are projected to decline 1% to 2%, while fourth-quarter organic sales are projected to decline 8% to 9%, with fourth-quarter adjusted EPS of $1.74 to $1.79.
Idex 8-K Report, Executive Changes (Oct 25, 2023)
IDEX Corporation (NYSE: IEX) announced on October 25, 2023 that Abhishek Khandelwal (also referred to in the press release as Abhi Khandelwal) will join as Senior Vice President and Chief Financial Officer, effective November 20, 2023. Mr. Khandelwal previously served at IDEX from 2010 until March 2020, most recently as Vice President of Finance Operations, Treasury and Financial Planning & Analysis. He most recently served as Chief Financial Officer of Multi-Color Corporation since January 2022, and before that as Senior Vice President and Chief Financial Officer of CIRCOR International, Inc. from April 2020 until December 2021. Upon his start date, Allison S. Lausas will cease serving as Interim Chief Financial Officer, a role she has held since September 2023, and will continue as Vice President and Chief Accounting Officer. CEO and President Eric Ashleman praised Ms. Lausas's leadership during the interim period. The filing sets out Mr. Khandelwal's compensation under an offer letter dated October 20, 2023: an initial base salary of $575,000, a 2024 incentive target of 75% of base salary, annual equity grants with a grant date fair value of $1,300,000, a new hire equity award with a grant date fair value of $2,000,000, and a $300,000 sign-on bonus subject to repayment if he leaves or is terminated for cause before the 12-month anniversary of his start date. Severance equals 12 months of base salary and target annual incentive upon termination without cause, rising to two times that amount if terminated within 24 months after a change in control.
Idex 8-K Report, Executive Changes (Aug 30, 2023)
IDEX Corporation announced on August 30, 2023 that Senior Vice President and Chief Financial Officer William K. Grogan is resigning to pursue a new professional opportunity, and that Allison S. Lausas will serve as interim Chief Financial Officer. Both changes are effective September 15, 2023. The filing states that Grogan's departure is not the result of any disagreement with the company's independent auditors or management on accounting principles, financial statement disclosure, or internal controls. Lausas, 43, has been with IDEX for two years as Vice President and Chief Accounting Officer and will keep that role during the interim period. She previously held roles of increasing responsibility at SunCoke Energy, Inc. from 2011 to 2021, most recently as interim Senior Vice President, Chief Financial Officer and Controller, and spent nine years at KPMG. In connection with her interim appointment, the Compensation Committee approved an award of 2,200 shares of restricted stock that cliff vests three years after the grant date, subject to continued service. IDEX has begun a search for a permanent CFO, considering both internal and external candidates. The filing describes IDEX as a company with more than 8,500 employees, manufacturing operations in more than 20 countries, and over $3.1 billion in annual sales.
Idex 8-K Report, Executive Changes (Aug 30, 2023)
IDEX Corporation (IEX), listed on the New York Stock Exchange, filed this Current Report on Form 8-K, dated August 24, 2023 and signed August 30, 2023, to disclose a leadership change. The filing reports that, as part of an internal reorganization of certain leadership positions, the company notified Marc Uleman, Senior Vice President, Group Executive, Health & Science Technologies, on August 24, 2023 that his position was being eliminated. The elimination takes effect September 11, 2023, and Mr. Uleman will no longer serve in an executive role after that date. The filing does not report any financial results, guidance, or other operating information, and it discloses no financial impact from the change. For investors, this is a limited, executive-level organizational update within the Health & Science Technologies group. The filing is signed by William K. Grogan, Senior Vice President and Chief Financial Officer.
Idex 8-K Report, Financial Results (Jul 27, 2023)
IDEX Corporation reported record second-quarter 2023 net sales of $846.2 million, up 6% overall and 3% organically, with reported diluted EPS of $1.82 (up 1%) and record adjusted diluted EPS of $2.18 (up 8%). Operating cash flow was $141.2 million and free cash flow was $119.6 million, up 24% from the prior year period. The company also lowered its full-year 2023 outlook: organic sales are now projected to decline 1 to 2 percent, with GAAP EPS of $6.80 to $6.90 and adjusted EPS of $7.90 to $8.00. Third-quarter organic sales are projected to decline 7 to 8 percent, with adjusted EPS of $1.84 to $1.89. management attributed the weaker outlook to its Health & Science Technologies segment, where customers' sharp inventory recalibration and demand softness followed two years of double-digit growth. Management said it no longer expects a market recovery in the second half of the year and is pursuing targeted cost reductions. Fluid & Metering Technologies and Fire & Safety / Diversified Products delivered strong organic growth and margin expansion. HST net sales were $339.5 million, with adjusted EBITDA margin down 420 basis points to 27.6%. Other developments in the filing include the completion of the Iridian Spectral Technologies acquisition on May 19, 2023 for $110.3 million in cash, and a $100.0 million private placement of 5.13% Senior Notes due 2028 used to repay 3.20% Senior Notes due June 13, 2023. Second-quarter net income margin fell 90 basis points to 16.4%, reflecting a reserve on an investment with a collaborative partner, higher amortization and higher interest expense.
Idex 8-K Report, Material Agreement (Jun 14, 2023)
IDEX Corporation completed a private placement on June 13, 2023 of $100 million aggregate principal amount of 5.13% Series C Senior Notes due June 13, 2028 (the "2028 Notes") under a Note Purchase and Master Note Agreement with NYL Investors LLC and certain affiliates of New York Life. The company used the proceeds to repay its 3.20% Series A Senior Notes due June 13, 2023, which were issued under a 2016 Note Purchase Agreement. The 2028 Notes are unsecured and rank pari passu with the company's other unsecured, unsubordinated debt, and they have not been registered under the Securities Act of 1933. The Purchase Agreement also establishes a shelf facility allowing IDEX to issue additional unsecured senior notes ("Shelf Notes") to New York Life affiliates and managed accounts, up to $300 million less the amount of outstanding 2028 Notes and senior notes under the 2016 agreement (currently $100 million of Series B Senior Notes due June 13, 2025). Shelf Notes may be issued through June 12, 2026, with maturities of no more than 15 years and rates to be mutually agreed after IDEX requests a purchase. The agreement contains restrictive covenants limiting asset transfers and sales, liens, indebtedness, affiliate transactions, and certain mergers or consolidations, and requires compliance with a leverage ratio, interest coverage ratio, and priority debt ratio. IDEX may prepay notes at par plus accrued interest plus a make-whole amount, in minimum increments of 5% of the outstanding series, and customary events of default apply.
Idex 8-K Report, Shareholder Vote Results (May 31, 2023)
IDEX Corporation filed this Form 8-K to report the results of its Annual Meeting of Stockholders, held on May 25, 2023. Stockholders elected four Class I directors, Katrina L. Helmkamp, Mark A. Beck, Carl R. Christenson and Alejandro Quiroz Centeno, to three-year terms expiring at the 2026 annual meeting. Votes for each nominee were 61,440,895, 54,152,966, 63,068,104 and 68,741,243, respectively, and each nominee received more votes for than against. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 65,328,418 affirmative votes against 3,605,508 negative votes. On the frequency of future advisory say-on-pay votes, a majority favored one year (68,633,788 votes), compared with 31,065 for two years and 549,410 for three years. Based on this result, the Board determined that the company will hold the advisory compensation vote every year. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2023, with 67,107,495 votes for and 3,369,771 against. A stockholder proposal calling for a report on hiring practices related to people with arrest or incarceration records did not pass, receiving 12,634,525 affirmative votes against 55,573,427 negative votes and 1,065,885 abstentions. Broker non-votes totaled 1,250,659 on the director, say-on-pay, frequency and stockholder proposal items, and the filing lists the Inline XBRL cover page as its only exhibit.
Idex 8-K Report, Financial Results (Apr 27, 2023)
IDEX Corporation (NYSE: IEX) reported first-quarter 2023 results on April 26, 2023, with record net sales of $845.4 million, up 13% overall and 6% organically compared with $751.1 million in the first quarter of 2022. Reported diluted EPS was $1.84 (up 1%), and adjusted diluted EPS was $2.09 (up 7%). Net income attributable to IDEX was flat at $139.8 million. Operating cash flow rose to $147.9 million and free cash flow to $121.3 million, both up sharply, driven mainly by lower investments in working capital. Orders declined 4% to $825.5 million, with organic orders down 10%. The key concern is the Health & Science Technologies (HST) segment, where customers indicated a larger and more prolonged inventory correction than previously communicated. HST organic sales grew 3%, but its adjusted EBITDA margin fell 300 basis points to 28.7%, and management now expects HST's 2023 revenue growth to be negative. In response, management lowered full-year 2023 adjusted EPS guidance to $8.25 to $8.55 per share from $8.50 to $8.80 previously, while reported EPS guidance is $7.30 to $7.60 and full-year organic sales growth is projected at 0 to 3 percent. IDEX also announced an agreement in April 2023 to acquire Iridian Spectral Technologies for 150 million Canadian dollars, expected to close in the second quarter of 2023 subject to customary conditions. The guidance excludes this pending acquisition and all future acquisitions.
Idex 8-K Report, Financial Results (Feb 1, 2023)
IDEX Corporation reported strong fourth quarter and record full year 2022 results in a press release dated January 31, 2023 (Exhibit 99.1), with accompanying earnings slides (Exhibit 99.2). For the fourth quarter, reported EPS was $1.71 (up 10%) and adjusted EPS was $2.01 (up 18%). Sales were $810.7 million, up 13% overall and 12% organically, and orders were $803.4 million, up 1% overall and 1% organically. Net income was $130.0 million, and Adjusted EBITDA was $218.9 million, with an Adjusted EBITDA margin of 27.0%. For full year 2022, the company reported record sales of $3.2 billion (up 15%, or 13% organically), record orders of $3.3 billion (up 8% overall and 5% organically), and record reported EPS of $7.71 (up 31%). Adjusted EPS was a record $8.12, up 18%. Net income was $586.7 million, and Adjusted EBITDA was a record $884.2 million. The company invested more than $1 billion across acquisitions, capital projects and share repurchases during the year, including the acquisition of Muon Group in November 2022 for cash consideration of $713.0 million, net of cash acquired. For 2023, management guided to full-year organic sales growth of 1% to 5%, GAAP EPS of $7.55 to $7.85 and adjusted EPS of $8.50 to $8.80. First quarter 2023 guidance calls for organic sales growth of 3% to 5% and adjusted EPS of $1.98 to $2.03. Management described 2023 as an uncertain period of transition, citing compression in the end-to-end order fulfillment cycle and broader macroeconomic shifts, and noted that the first quarter outlook reflects OEM shipment delays and the timing of share-based compensation recognition.
Idex 8-K Report, Regulation FD Disclosure (Dec 16, 2022)
On December 16, 2022, IDEX Corporation announced that its Chief Operating Decision Maker will change the segment measure of profit and loss from operating income to adjusted earnings before interest, income taxes, depreciation and amortization (Adjusted EBITDA), effective for the quarter ending December 31, 2022. Adjusted EBITDA excludes items such as fair value inventory step-up charges, restructuring expenses and asset impairments, the net impact from the exit of a COVID-19 testing application, gains on the sale of a business and of assets, corporate transaction indemnity settlements, loss on early debt redemption, and the noncash loss related to termination of the U.S. pension plan. The company states the change aligns with how resources are allocated and businesses are evaluated, and that it affects only how segment results were previously reported. It does not revise consolidated financial statements for any prior period. Exhibit 99.1 furnishes unaudited segment information for the full year 2021 and for each quarter of 2021 and of 2022 through September 30, 2022. For the full year 2021, IDEX reported net sales of $2,764.8 million, reported operating income of $637.0 million and Adjusted EBITDA of $765.4 million, a stated Adjusted EBITDA margin of 27.7%. For the third quarter of 2022, net sales were $824.0 million, or $806.1 million on an adjusted basis after a $17.9 million revenue acceleration tied to a customer's decision to discontinue commercializing its COVID-19 testing application. Third-quarter Adjusted EBITDA was $231.4 million, a stated margin of 28.7%. Third-quarter reported net income of $178.7 million included a $34.8 million gain on sale of a business. Across the segments reported (FMT, HST and FSDP), Adjusted EBITDA rose quarter over quarter through 2022, from $214.7 million in the first quarter to $219.2 million in the second and $231.4 million in the third. Investors should note that the filing presents these figures on the new basis, and the segment information is unaudited.
Idex 8-K Report, Regulation FD Disclosure (Nov 18, 2022)
On November 18, 2022, IDEX Corporation (NYSE: IEX) completed its previously announced acquisition of Muon B.V., a private limited liability company in the Netherlands, and its subsidiaries (together, "Muon Group"). The company furnished a press release announcing the closing as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). According to the press release, Muon Group is a micro-precision technology manufacturer based in the Netherlands that produces highly precise flow paths in a variety of materials. These enable the movement of liquids and gases in critical applications across medical technologies, semiconductor, food processing, digital printing and filtration. The group includes LouwersHanique, Veco, Millux, Tecan and Atul. Muon Group will report into IDEX's Health & Science Technology (HST) segment. The press release describes Muon Group as an "IDEX-like collection of businesses" with a values-based culture similar to IDEX's. The filing's forward-looking statements cite the expected benefits of the acquisition and identify IDEX's ability to integrate Muon Group as one of several risk factors. The filing does not state the purchase price or the financial contribution of the acquired business.
Idex 8-K Report, Financial Obligation (Nov 17, 2022)
IDEX Corporation (IEX) disclosed under Item 2.03 that on November 10, 2022 it drew approximately $200 million from its term credit facility, and on November 10 and November 15, 2022 made additional draws totaling approximately $168 million from its revolving credit facility. The borrowings were made under the Amended and Restated Credit Agreement dated November 1, 2022, with Bank of America, N.A. as administrative agent, along with other lenders named in the filing. The company states that the proceeds will be used to finance a portion of the consideration for its previously announced acquisition of Muon B.V., a private limited liability company in the Netherlands, and its subsidiaries. The filing describes that acquisition only as previously announced, without further terms in this document. Borrowings under the Credit Agreement mature on November 1, 2027 and bear interest at either an alternate base rate or Term SOFR rate (or appropriate alternative currency reference rates), plus an applicable margin based on the better of the company's senior unsecured long-term debt rating or its applicable leverage ratio. A copy of the Credit Agreement was previously filed as Exhibit 10.1 to the company's Form 8-K filed November 2, 2022.
Idex 8-K Report, Material Agreement (Nov 2, 2022)
IDEX Corporation entered into an Amended and Restated Credit Agreement on November 1, 2022, with Bank of America, N.A. as administrative agent and a group of co-agents and lenders, amending and restating its Credit Agreement originally dated May 31, 2019. The filing describes a $800 million revolving credit facility with a final maturity of November 1, 2027, extended from the May 30, 2024 maturity of the original agreement, with a provision for one additional one-year extension under certain conditions. Up to $100 million of the revolver is available for letters of credit and up to $50 million for same-day swing line loans. Proceeds may be used for working capital, general corporate purposes, and refinancing existing company and subsidiary debt, and the company may request commitment increases of up to $400 million in aggregate. The agreement also includes a $200 million term credit facility with a final maturity of November 1, 2027. The company has not yet drawn on the term facility, which may be requested before March 3, 2023, with proceeds available to pay a portion of the consideration for its previously announced acquisition of Muon Group B.V. Borrowings bear interest at an alternate base rate or Term SOFR (or alternative currency rates) plus an applicable margin tied to the better of the company's senior unsecured long-term debt rating or its leverage ratio. The agreement permits an optional ESG-linked pricing amendment and includes interest coverage and leverage ratio covenants tested quarterly, along with customary negative covenants and events of default. The filing also notes that IDEX maintains other commercial and investment banking relationships with the lenders and their affiliates. The full credit agreement is filed as Exhibit 10.1 and is incorporated by reference, and the filing states that certain schedules were omitted under Item 601(a)(5) of Regulation S-K and will be furnished to the SEC upon request.
Idex 8-K Report, Financial Results (Oct 26, 2022)
IDEX Corporation (NYSE: IEX) reported record third-quarter 2022 results for the period ended September 30, 2022. Reported EPS was $2.36 (up 56%) and adjusted EPS was $2.14 (up 20%). Net sales were a record $824.0 million, up 16% overall and 15% organically versus Q3 2021. Operating margin was 24.5% reported and 24.9% adjusted, up 190 and 60 basis points. Cash from operations was $198.1 million and free cash flow was $181.8 million. The company raised its full-year 2022 guidance. Reported EPS is now expected at $7.75 to $7.80 (previously $7.19 to $7.29 per the presentation's prior guidance column), and adjusted EPS at $8.04 to $8.09. Full-year organic sales growth is projected at about 12%, with about 9% organic growth expected in the fourth quarter. Fourth-quarter reported EPS is guided to $1.75 to $1.80. Management highlighted the pending acquisition of Muon Group for €700.0 million in cash, expected to close by the end of the fourth quarter of 2022 subject to regulatory approval, and the September 9, 2022 sale of Knight LLC for $49.4 million net of cash remitted, which produced a $34.8 million pre-tax gain. The quarter also included a $16.8 million impairment and $17.9 million of accelerated deferred revenue tied to the exit of a COVID-19 testing application, which was a net $1.1 million operating income impact.
Idex 8-K Report, Executive Changes (Sep 22, 2022)
IDEX Corporation (NYSE: IEX) filed a Form 8-K on September 22, 2022 to report a leadership change on its Board of Directors. William M. Cook notified the Company on September 19, 2022 of his decision to retire from the Board and as Non-Executive Chairman, effective October 1, 2022. The filing states that his retirement is not due to any disagreement with the Company on its operations, policies or practices. Cook had also served as an independent director, Lead Director, and as a member and Chair of the Audit Committee. Katrina L. Helmkamp was appointed by the Board as its new Non-Executive Chair, effective October 1, 2022. The accompanying press release (Exhibit 99.1) notes that she has served as an independent director since November 2015 and has chaired the Nominating and Corporate Governance Committee. The release also states that with Cook's departure the size of the Board will decrease from 11 to 10 directors. For investors, the filing is a governance update rather than a financial disclosure. It includes no financial results, guidance, or compensation terms for the new Chair in the filing text. The release describes IDEX as having nearly $2.8 billion in annual sales and more than 8,000 employees.
Idex 8-K Report, Regulation FD Disclosure (Sep 13, 2022)
IDEX Corporation (NYSE: IEX) announced on September 13, 2022 that it has entered into a signing protocol under which, after completing consultation with the relevant Dutch works council, it will enter into a Sale and Purchase Agreement to acquire Muon B.V. and its subsidiaries ("Muon Group") from Rivean Capital, a European mid-market private equity firm, for cash consideration of €700 million. Muon Group manufactures highly precise flow paths in a variety of materials that enable the movement of liquids and gases in critical applications across medical technologies, semiconductor, food processing, digital printing, and filtration. According to the press release furnished as Exhibit 99.1, Muon Group is expected to generate FY 2022 sales of approximately €140 million and EBITDA margins of approximately 33 percent. The business will join the Scientific Fluidics & Optics group within IDEX's Health & Science Technology segment. The company expects the transaction to close in the fourth quarter of 2022, subject to regulatory approvals, the Dutch works council consultation, and customary closing conditions. IDEX expects to fund the acquisition with cash on hand and proceeds from its revolving credit facility. Management characterized the deal as part of its disciplined capital deployment strategy and said Muon Group is an "IDEX-like" business with synergy potential alongside existing Health & Science businesses. The filing notes that IDEX has not reconciled the expected EBITDA contribution of Muon Group to GAAP net income, citing the difficulty of quantifying certain amounts without unreasonable efforts.
Idex 8-K Report, Financial Results (Jul 27, 2022)
IDEX Corporation reported second-quarter 2022 results for the period ended June 30, 2022, with net sales of $796.1 million, up 16% overall and 12% organically versus Q2 2021, and reported diluted EPS of $1.81 versus $1.34 a year earlier. Record adjusted diluted EPS was $2.02, up 15.4% from $1.75. Reported operating margin was 23.4%, up 30 basis points, while adjusted operating margin declined 60 basis points to 23.8%, which management attributes in part to incremental acquisition-related amortization of $5.9 million. Orders were $839 million, up 12% overall and 7% organically. Cash generation weakened in the quarter. Cash flow from operating activities was $112.3 million, down 17.6%, mainly due to higher working capital, and free cash flow was $96.7 million. Management cited higher receivables from increased volume and higher inventories to support production amid supply chain difficulties. The company repurchased 475 thousand shares in the quarter, completed the KZValve acquisition for $120.2 million in cash on May 2, 2022, and increased its dividend by 11%. IDEX raised its full-year 2022 guidance: reported EPS is now $7.19 to $7.29 (previously $6.87 to $7.00) and adjusted EPS is $7.88 to $7.98 (previously $7.50 to $7.63). Full-year organic sales growth is projected at approximately 10%, and third-quarter organic growth at 9 to 10%. The filing's forward-looking statements flag risks including COVID-19, Russia's invasion of Ukraine, inflation, rising interest rates, and supply chain constraints.
Idex 8-K Report, Executive Changes (Jun 16, 2022)
IDEX Corporation (NYSE: IEX) filed a Current Report on Form 8-K reporting that its Board of Directors appointed Alejandro Quiroz Centeno as a director and as a member of the Compensation Committee, effective June 15, 2022. The appointment increases the size of the Board from 10 to 11 members. The filing states that Mr. Quiroz has no familial relationships or related party transactions with the Company requiring disclosure under Items 401(d) or 404(a) of Regulation S-K, and that he was not selected pursuant to any arrangement or understanding with any other person. According to the accompanying press release (Exhibit 99.1), Mr. Quiroz currently serves as CEO Latin America for Prysmian Group, and previously served as President of Aptiv Latin America, a business the release describes as having $5.5 billion in revenue and 75,000 employees. Mr. Quiroz will participate in the non-employee director compensation arrangements described in the Company's Definitive Proxy Statement filed March 23, 2022. The press release quotes CEO Eric D. Ashleman noting that more than half of IDEX revenue now comes from outside the United States, and quotes Chairman William M. Cook on the value Mr. Quiroz will bring to the Board. The filing is primarily a governance update rather than a financial disclosure, and it contains no financial results or guidance.
Idex 8-K Report, Executive Changes (May 10, 2022)
IDEX Corporation reported in a Form 8-K filed May 10, 2022 that the stockholder actions taken at its 2022 Annual Meeting of Stockholders, held May 6, 2022, were completed. Ernest J. Mrozek retired from the Board following the meeting, and the Board fixed the number of directors at ten. At the meeting, stockholders elected Livingston L. Satterthwaite, David C. Parry and Eric D. Ashleman as Class III directors for three-year terms expiring at the 2025 annual meeting. They also elected L. Paris Watts-Stanfield as a Class II director for the remaining two-year term expiring at the 2024 annual meeting. Vote counts for Satterthwaite (57,630,784 for and 10,904,074 against) and Parry (61,206,475 for and 7,328,331 against) were less favorable than for Ashleman (67,750,926 for and 782,225 against) and Watts-Stanfield (68,324,563 for and 210,458 against). Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 68,035,653 votes for and 5,481,758 against. They ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2022, with 66,308,845 votes for and 3,725,285 against. The filing lists 1,488,611 broker non-votes on the director and say-on-pay proposals, and the exhibit listed in Item 9.01 is only the Inline XBRL cover page file.
Idex 8-K Report, Financial Results (Apr 27, 2022)
IDEX Corporation reported record first-quarter 2022 results for the three months ended March 31, 2022, according to a press release furnished as Exhibit 99.1 and presentation slides furnished as Exhibit 99.2. Net sales were $751.1 million, up 15% overall and 12% organically versus the prior-year period, with record reported EPS of $1.83 (up 24%) and record adjusted EPS of $1.96 (up 21%). Reported operating margin was 25.0%, up 110 basis points, and adjusted EBITDA was $214.7 million. Orders reached a record $856 million, up 20% overall and 16% organically. Cash flow was weaker: cash from operating activities was $79.7 million, down 27.1%, mainly from higher working capital, and free cash flow was $63.6 million. Cash and cash equivalents fell to $733.2 million from $855.4 million at year-end 2021, reflecting the $114.7 million Nexsight acquisition (completed February 28, 2022, paid entirely in cash on hand) and $26.3 million of share repurchases. For 2022, IDEX projects full-year organic sales growth of 6% to 8% and reported EPS of $6.87 to $7.00 (adjusted EPS of $7.50 to $7.63). For the second quarter, it expects 8% to 9% organic sales growth and reported EPS of $1.69 to $1.74. The company also announced an agreement on March 30, 2022 to acquire KZValve for $120.0 million in cash, with closing expected by the end of the second quarter of 2022, subject to regulatory approval and customary closing conditions.
Idex 8-K Report, Executive Changes (Feb 28, 2022)
IDEX Corporation (NYSE: IEX) filed this Current Report on Form 8-K to disclose the appointment of L. Paris Watts-Stanfield to its Board of Directors. The Board appointed Ms. Watts-Stanfield on February 23, 2022, effective February 25, 2022, increasing the size of the Board from 10 to 11 members. She will also serve on the Audit Committee and will participate in the compensation arrangements for non-employee directors described in the Company's Definitive Proxy Statement filed on March 23, 2021. According to the accompanying press release (Exhibit 99.1), Ms. Watts-Stanfield currently serves as Vice President and Chief Financial Officer, Greater China, of Medtronic, Inc. Her career includes corporate finance and audit roles at Medtronic, Alcoa, Wal-Mart, and Procter & Gamble. She holds an MBA from the University of Rochester, Simon School of Management, and a bachelor's degree in Mathematics from the State University of New York. Chairman William M. Cook and CEO Eric D. Ashleman cited her global business skills and her perspective on financial systems, controls, and ESG commitments. The filing describes a board appointment rather than a financial result, and it contains no financial performance figures. The press release states that IDEX has more than 7,500 employees, manufacturing operations in more than 20 countries, and nearly $2.8 billion in sales.
Idex 8-K Report, Executive Changes (Feb 8, 2022)
IDEX Corporation filed this Form 8-K under Item 5.02 to report the planned departure of Denise R. Cade, its Senior Vice President, General Counsel and Corporate Secretary. The Company received notice from Ms. Cade on February 3, 2022, of her intention to resign from these roles. According to the filing, Ms. Cade's resignation will be effective February 25, 2022, and she is leaving to pursue another employment opportunity. The filing describes no other changes to the Company's directors or officers. For investors, the filing is a routine notice of a senior legal and governance officer's departure with a stated effective date. Its only exhibit is the Cover Page Interactive Data File (Exhibit 104), which carries the cover page XBRL tags embedded in the Inline XBRL document.
Idex 8-K Report, Financial Results (Feb 2, 2022)
IDEX Corporation (NYSE: IEX) reported record fourth-quarter and full-year 2021 results, with full-year reported net sales of $2,764.8 million (up 18% overall and 12% organically versus 2020), reported diluted EPS of $5.88 and adjusted diluted EPS of $6.30. Fourth-quarter net sales were $714.8 million, up 16% overall and 11% organically, with record orders of $795.3 million. Full-year operating margin was 23.0% and adjusted operating margin was 23.9%. Management said demand for its differentiated technology remains strong, particularly in its Health & Science Technologies markets, but expects supply chain and COVID-19 challenges to continue through the first half of 2022, affecting its ability to ramp production. For 2022, IDEX guided to organic sales growth of 5% to 8% for the full year and 6% to 7% in the first quarter, with GAAP EPS of $6.70 to $7.00 (adjusted EPS of $7.33 to $7.63) for the full year and $1.57 to $1.60 (adjusted $1.73 to $1.76) for the first quarter. Beginning in 2022, the company will exclude after-tax acquisition-related intangible asset amortization from adjusted EPS; on that restated basis, 2021 adjusted EPS was $6.87 for the full year and $1.71 for the fourth quarter. During 2021, IDEX invested more than $650 million in acquisitions and capital projects, including the ABEL Pumps, Airtech and CiDRA Precision Services transactions. It also agreed on November 23, 2021 to acquire Nexsight, LLC for $120.0 million in cash, expected to close by the end of the first quarter of 2022, subject to regulatory approval. Cash flow from operations was $565.3 million and free cash flow was $492.6 million for the full year, while cash and cash equivalents ended the year at $855.4 million.
Idex 8-K Report, Financial Results (Oct 27, 2021)
IDEX Corporation reported record third-quarter 2021 results for the period ended September 30, 2021, according to a press release dated October 26, 2021 (Exhibit 99.1). Orders were $774.2 million, up 36 percent overall and 28 percent organically compared with Q3 2020. Sales were $712.0 million, up 23 percent overall and 15 percent organically. Reported operating margin was 22.6 percent and adjusted operating margin was 24.3 percent. Reported EPS was $1.51 and adjusted EPS was $1.63, an increase of 16.4 percent from the adjusted prior-year period. Cash from operations was $156.6 million and free cash flow was $141.7 million. Management guided to fourth-quarter organic sales growth of 9 to 10 percent and EPS of $1.55 to $1.58, assuming output similar to the third quarter, a step-up in targeted investments, and potential year-end logistics challenges. For the full year, the company maintained its projection of 11 to 12 percent organic sales growth and narrowed its adjusted EPS range to $6.30 to $6.33 from the prior $6.26 to $6.36. Management said the ABEL Pumps and Airtech acquisitions are performing well and that the balance sheet has ample capital for organic investment and M&A. The filing also cites ongoing supply chain constraints, inflation, and logistics challenges as pressures on results. The filing furnishes the press release and a slide presentation (Exhibit 99.2) for the quarterly earnings conference call held October 27, 2021. The materials include reconciliations of non-GAAP measures and note a $9.1 million pre-tax fair value inventory step-up charge tied to the Airtech acquisition.